Your session is about to expire
← Back to Search
Acalabrutinib + Rituximab for Chronic Lymphocytic Leukemia
Study Summary
This trial is testing a new combination of drugs to treat CLL/SLL. The combo is designed to be safer and more effective than current treatments.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 2 trial • 177 Patients • NCT04346199Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a condition that causes frequent or severe bleeding.You have been experiencing very heavy night sweats for more than a month.You are able to swallow pills and keep them down in your stomach.You have a condition called autoimmune hemolytic anemia or immune thrombocytopenic purpura (ITP) that is not well controlled.You are taking blood thinners like warfarin or other similar medications within a week of starting the study drug.You have symptoms like fatigue, weight loss, or pain that are not caused by an infection.Your overall physical condition is good, with a performance status score of 2 or less, unless it is specifically related to chronic lymphocytic leukemia (CLL).You have chest pain (angina) that doesn't get better with medication.Your spleen is swollen and causing significant symptoms or is growing rapidly in size.You have very large, growing, or causing symptoms, swollen lymph nodes.You have a type of anemia or low platelet count caused by an autoimmune condition that doesn't improve with common treatments like corticosteroids.You have lost a lot of weight (more than 10% of your body weight) without trying in the past 6 months.You experience extreme tiredness that affects your daily activities.You have experienced a severe allergic reaction called anaphylaxis in the past when receiving certain medications for your condition.You have been diagnosed with or are suspected to have a condition called progressive multifocal leukoencephalopathy (PML).You have experienced bleeding in the brain or a stroke within the past 6 months.You have a condition in your stomach or intestines that makes it hard for your body to absorb medicine taken by mouth.
- Group 1: Acalabrutinib and Rituximab treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what indications is Acalabrutinib typically prescribed?
"Acalabrutinib is regularly employed to manage diffuse large b-cell lymphoma (DLBCL). Additionally, this prescription can be used in association with numerous other clinical conditions such as B-Cell Lymphomas, Polyangium, and Pemphigus Vulgaris."
Is Acalabrutinib hazardous to patients' health?
"Acalabrutinib has been assessed to have a safety rating of 2. This is due to its Phase 2 trial status, which suggests that while there are some data points affirming the drug's security, none exist as evidence for efficacy."
Is there a possibility of enrolling in this experiment as an experimental subject?
"Clinicaltrials.gov reveals that this clinical trial, which first appeared on March 25th 2019 and was last edited on February 7th 2022, is not currently recruiting participants. Nevertheless, 3319 other trials are still accepting patients at the moment."
What is the maximum capacity of participants in this medical experiment?
"This clinical experiment is no longer enrolling participants. It was initially published on March 25th 2019 and its last update occurred on February 7th 2022. If you are seeking other research opportunities, 2862 studies for leukemia, lymphocytic, chronic B-cell have openings as well as 457 trials that involve the medication Acalabrutinib."
Share this study with friends
Copy Link
Messenger